Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Page Banner for mobile screens

Industry Expert Theater Sessions at ASCO 2024: Showcasing Innovations in Cancer Diagnostics

Innovations in Cancer Diagnostics | ASCO 2024

As the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting approaches at the end of this month, anticipation is building around the upcoming data presentations from leading companies in the field of oncology diagnostics. Notable names like Predicine, Natera, Guardant Health, Precede Biosciences, GRAIL, Exact Sciences, Burning Rock Biotech, SAGA Diagnostics, HaploX Biotechnology, Personalis, Foresight, Illumina, and others will be showcasing their latest clinical study findings. These presentations promise to highlight significant advancements and innovations in cancer diagnostics, setting the stage for exciting developments in the fight against cancer.

In addition to other sessions, GRAIL, Exact Sciences, and Tempus will also participate in the Industry Expert Theater sessions. GRAIL and Exact Sciences are poised to showcase the paradigm shift in cancer screening through multi-cancer early detection tests. Tempus, on the other hand, will present its advanced AI technology and expanded molecular portfolio, which includes minimal residual disease detection and monitoring.

The Industry Expert Theater (IET) brings together industry leaders and attendees for 45-minute, non-accredited educational presentations on the latest in oncology practices, products, services, and technologies. Below is the list of Industry Expert Theater (IET) presentations to be presented at the upcoming ASCO meeting under the diagnostic criteria:

Date and Time

Title

Description

Company

Presenters

Location

Saturday, June 1, 2024

9:30 AM – 10:30 AM CDT

Changing the Paradigm: Use of a Multi-Cancer Early Detection Test to Screen for Many Aggressive Cancers That Lack Recommended Screenings

GRAIL’s multi-cancer early detection test uses ctDNA to screen for and locate many of the deadliest cancers with no recommended screening. Hear what oncologists need to know, including learnings from 3 years in clinical practice.

Megan Hall, PhD, Distinguished Scientist, GRAIL, LLC


Rita Shaknovich, MD, PhD, VP Medical Affairs, GRAIL, LLC


Eric Klein, MD, PhD, Distinguished Scientist, GRAIL, LLC

Theater 2

Saturday, June 1, 2024

3:00 PM – 4:00 PM CDT

Transforming Precision Medicine: AI and Molecular Insights Intersect Across the Cancer Care Continuum

Discover the rapid evolution of precision oncology with our cutting-edge AI technology and expanded molecular portfolio, now including MRD and monitoring, to enhance the delivery of comprehensive insights to providers and biopharma professionals.


Tempus | AI-enabled precision medicine

Ezra Cohen, MD, FASCO, Chief Medical Officer, Tempus


Kate Sasser, PhD, Chief Scientific Officer, Tempus


Halla Nimeiri, MD, Chief Development Officer, Tempus

Theater 2

Sunday, June 2, 2024

9:45 AM – 10:45 AM CDT

Pioneering a Paradigm Shift in Cancer Screening: The Era of Multi-Cancer Early Detection Testing

Single-organ cancer screening won’t be enough to stop cancer from becoming the #1 cause of death. Multi-cancer Early Detection tests show promise in early cancer detection. Learn how a rigorous approach to MCED test development may lead to the paradigm shift that helps reduce the burden of cancer.


Exact Sciences logo [IMAGE] | EurekAlert! Science News Releases

Tomasz M. Beer, MD, FACP, Chief Medical Officer and VP, Multi-cancer Early Detection, Exact Sciences


Frank Diehl, PhD, SVP Research and Development, Multi-cancer Early Detection, Exact Sciences

Theater 1

 

Tags:

Executive Summary

As the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting approaches at the end of this month, anticipation is building around the upcoming data presentations from leading companies in the field of oncology diagnostics.

Recent Articles